Latest News And Breaking Headlines

New nanoparticle drug delivery system improves treatment of atherosclerosis

Nieuw medicijnafgiftesysteem verbetert de behandeling van atherosclerosesmall (2022). DOI: 10.1002/smll.202200967″ width=”800″ height=”306″/>

Theranostic nanoparticles (NPs) synthesized using n-butyl cyanoacrylate (BCA). Air-trapped NPs were synthesized using the sonication-based mini-emulsion method. The monomer BCA is emulsified in the aqueous phase and loaded with 2-hydroxypropyl-beta-cyclodextrin (CD) and indocyanine green (ICG)/IR780 dye. During the generation step, air is trapped in the NPs. Intravenously injected CD-loaded NPs will accumulate on the atherosclerotic plaque and release CD, reducing plaque size. The ICG/IR780-loaded and air-trapped NPs provided contrast enhancement via NIR fluorescence and ultrasound. The generated theranostic NPs allow both the identification/diagnosis of atherosclerosis and effective anti-atherosclerotic therapy. Credit: Sourabh Mehta et al, Small (2022). DOI: 10.1002/smll.202200967

Researchers from Baker Heart and Diabetes Institute have designed and developed a new drug delivery method that could vastly improve the efficacy of a drug to treat atherosclerosis and has the potential to identify and treat other diseases.

The technique, which uses drug-loaded nanoparticles, directly targets the site of atherosclerosis in animal models, improving the uptake of the drug hydroxylpropyl-beta-cyclodextrin (CD) by the cells and significantly lowering cholesterol levels, more effectively than the drug alone.

Currently, high doses of CD are required during the treatment of atherosclerosis, resulting in side effects, including hearing loss, but sustained and local release of this drug-loaded nanoparticle (CDNP), would not only improve the drug’s efficacy, but would likely decrease it. those negative effects.

The study, led by the deputy director of the Baker Institute, professor of basic and translation science Karlheinz Peter, was published in the journal Small this week.

“We know that CD lowers cholesterol levels in dental plaque, but it’s difficult to get the drugs into the needed area, so you need a large amount,” said co-investigator and Baker Institute Laboratory Head, Molecular Imaging and Theranostics Associate Professor Xiaowei Wang.

“We packaged the drug into the nanoparticle, which can be sent directly to the site of the disease. Once there, the drug accumulates and removes cholesterol.

“We already know that CD is an effective treatment for other diseases, including Alzheimer’s disease and Niemann-Pick type C disease, so this technique has the potential to improve treatment efficacy for those diseases as well.”

The nanoparticles have the added benefit of a gas core and fluorescent dye coating, allowing them to be used as a contrast agent for diagnostic imaging, Wang said.

“We can also visualize the nanoparticles on ultrasound, which would be a valuable diagnostic tool, and pop the drug-filled bubble for immediate drug delivery using an ultrasound wave,” she said.

“We believe that these CDNPs provide a platform for diagnostic and therapeutic delivery of anti-atherosclerotic therapy, and that CD carrier platforms such as CDNPs can be used for the co-administration of multiple potent drugs.”

New combination of nanoparticles for atherosclerosis developed

More information:
Sourabh Mehta et al, An ultrasound-responsive theranostic cyclodextrin-loaded nanoparticle for multimodal imaging and therapy for atherosclerosis, Small (2022). DOI: 10.1002/smll.202200967

Journal information:

Provided by Baker Heart and Diabetes Institute

Quote: New nanoparticle drug delivery system improves atherosclerosis treatment (2022, June 23) Retrieved June 24, 2022 from https://phys.org/news/2022-06-nanoparticle-drug-delivery-treatment-atherosclerosis.html

This document is copyrighted. Other than fair dealing for personal study or research, nothing may be reproduced without written permission. The content is provided for informational purposes only.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More